In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain

Psychopharmacology

Volumn 191, Issue 3, 2007, Pages 745-758

  Bortolozzi, A ^a   Diaz Mataix L ^a   Toth, M ^b   Celada, P ^a   Artigas, F ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antipsychotic; Dopamine; Dopamine receptors; Dorsal raphe; Prefrontal cortex; Schizophrenia; Serotonin; Serotonin receptor; Ventral tegmental area

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; APOMORPHINE; ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DORSAL RAPHE NUCLEUS; INTRACELLULAR RECORDING; KNOCKOUT MOUSE; MALE; MICRODIALYSIS; MOUSE; NEUROMODULATION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM; VENTRAL TEGMENTUM; WILD TYPE;

ACTION POTENTIALS; ANIMALS; ANTIPSYCHOTIC AGENTS; AUTORECEPTORS; BRAIN; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; HALOPERIDOL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRODIALYSIS; PIPERAZINES; PREFRONTAL CORTEX; QUINOLONES; RAPHE NUCLEI; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, DOPAMINE D2; SEROTONIN; SEROTONIN AGONISTS; VENTRAL TEGMENTAL AREA;

EID: 33847690299     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-0698-y     Document Type: Article

References (81)

1. Adell A, Casanovas JM, Artigas F (1997) Comparative study in the rat of the actions of different types of stress on the release of 5-HT in raphe nuclei and forebrain areas. Neuropharmacology 36:745-751
2. Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR, Lewis DA (1999) Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 156:1580-1589
3. Amano T, Matsubayashi H, Momiyama T, Ishihara K, Todo N, Sasa M (1995) Antagonizing effects of a novel antipsychotic quinolinone derivative (OPC-14597) on dopaminergic inhibition of neuronal activities in the nucleus accumbens. Prog Neuropsychopharmacol Biol Psychiatry 19:105-116
4. 2A receptors in prefrontal cortex. Cereb Cortex 14:281-299
5. Andrade R, Malenka RC, Nicoll RA (1996) A G protein couples serotonin and GABAB receptors to the same channels in hippocampus. Science 1986(234):1261-1265
6. 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40:399-412
7. Arborelius L, Chergui K, Murase S, Nomikos GG, Hook BB, Chouvet G, Hacksell U, Svensson TH (1993a) The 5-HT(1A) receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn-Schmiedeberg's Arch Pharmacol 347:353-362
8. Arborelius L, Nomikos GG, Hacksell U, Svensson TH (1993b) (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol Scand 148:465-466
9. Assié MB, Ravailhe V, Faucillon V, Newman-Tancredi A (2005) Contrasting contribution of 5-hydroxytryptamine-1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 315:265-272
10. 1A receptor agonist: in vivo profile in neurochemical and behavioural models of serotonergic activity. Eur Neuropsychopharmacol 16(Suppl 4):S233
11. Bardin L, Kleven MS, Barret-Grevoz C, Depoortere R, Newman-Tancredi A (2006) Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. Neuropsychopharmacology 31:1869-1879
12. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104
13. Bortolozzi A, Artigas F (2003) Control of 5-hydroxytryptamine release in the dorsal raphe nucleus by the noradrenergic system in rat brain. Role of alpha-adrenoceptors. Neuropsychopharmacology 28:421-434
14. Bortolozzi A, Amargos-Bosch M, Adell A, Diaz-Mataix L, Serrats J, Pons S, Artigas F (2003) In vivo modulation of 5-hydroxytryptamine release in mouse prefrontal cortex by local 5-HT(2A) receptors: effect of antipsychotic drugs. Eur J Neurosci 18:1235-1246
15. 1Aeceptor knockout mice. J Neurochem 88:1373-1379
16. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 94:2569-2574
17. 1A and dopamine D-2S receptors coupled to extracellular signal-regulated kinase. Eur J Pharmacol 534:63-70
18. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389
19. Celada P, Paladini CA, Tepper JM (1999) GABAergic control of rat substantia nigra dopaminergic neurons: role of globus pallidus and substantia nigra pars reticulata. Neuroscience 89:813-825
20. Celada P, Puig MV, Casanovas JM, Guillazo G, Artigas F (2001) control of raphe serotonin neurons by the medial prefrontal cortex. Involvement of serotonin 1A, GABA (A) and glutamate receptors. J Neurosci 21:9917-9924
21. Chiodo LA (1988) Dopamine-containing neurons in the mammalian central nervous system: electrophysiology and pharmacology. Neurosci Biobehav Rev 12:49-91
22. Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3:1607-1619
23. Cosi C, Carilla-Durand E, Assié MB, Ormiere AM, Maraval M, Leduc N, Newman-Tancredi A (2005) Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur J Pharmacol 535:135-44
24. Cox RF, Meller E, Waszczak BL (1993) Electrophysiological evidence for a large receptor reserve for inhibition of dorsal raphe neuronal firing by 5-HT(1A) agonists. Synapse 14:297-304
25. Dahan L, Mnie-Filali M, Arnt J, Hertel P, Hadjeri N (2006) Effects of bifeprunox on the rat ventral tegmental area dopamine and dorsal raphe serotonin neuronal activity. Eur Neuropsychopharmacol 16(Suppl 4):S429
26. DeLeon A, Patel NC, Crismon ML (2004) Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26:649-666
27. Devivo M, Maayani S (1985) Inhibition of forskolin-stimulated adenylate-cyclase activity by 5-HTreceptor agonists. Eur J Pharmacol 119:231-234
28. 1A receptors in prefrontal cortex in the modulation of dopaminergic activity. Role in atypical antipsychotic action. J Neurosci 25:10831-10843
29. 1A receptor agonist. Eur Neuropsychopharmacol 16:288-296
30. Elvevag B, Goldberg TE (2000) Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 14:1-21
31. Fa M, Mereu G, Ghiglieri V, Meloni A, Salis P, Gessa GL (2003) Electrophysiological and pharmacological characteristics of nigral dopaminergic neurons in the conscious, head-restrained rat. Synapse 48:1-9
32. Ferré S, Cortes R, Artigas F (1994) Dopaminergic regulation of the serotonergic raphe-striatal pathway: microdialysis studies in freely moving rats. J Neurosci 14:4839-4846
33. Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. Academic, San Diego
34. Gessa GL, Devoto P, Diana M, Flore G, Melis M, Pistis M (2000) Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex. Neuropsychopharmacology 22:642-649
35. Gobert A, Rivet JM, Cistarelli L, Melon C, Millan MJ (1999) Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin(1A) receptors and blockade of alpha(2)-adrenergic receptors underlie its actions. Neuroscience 93:1251-1262
36. Goldner EM, Hsu L, Waraich P, Somers JM (2002) Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry 47:833-843
37. Grace AA, Bunney BS (1984) The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci 4:2877-2890
38. Green B (2004) Focus on aripiprazole. Curr Med Res Opin 20:207-213
39. Grunder G, Carlsson A, Wong DF (2003) Mechanism of new antipsychotic medications - occupancy is not just antagonism. Arch Gen Psychiatry 60:974-977
40. Harvey PD, Keefe RSE (2001) Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158:176-184
41. Hoyer D, Boddeke HGWM (1993) Antagonists, agonists, partial agonists: dilemmas of definition. Trends Pharmacol Sci 14:270-275
42. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76:1521-1531
43. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (2002) The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441:137-140
44. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA (2004) In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 483:45-53
45. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000) Relationship between dopamine D-2 occupancy, clinical response, and side effects: a double-blind PET study of firstepisode schizophrenia. Am J Psychiatry 157:514-520
46. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S (1995) 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)- quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity, J Pharmacol Exp Ther 274:329-336
47. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 93:9235-9240
48. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612-627
49. Lejeune F, Millan MJ (1998) Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)(1A) receptors: WAY 100, 635-reversible actions of the highly selective ligands, flesinoxan and S-15535. Synapse 30:172-180
50. Lewis DA, Lieberman JA (2000) Catching up on schizophrenia: natural history and neurobiology. Neuron 28:325-334
51. Li Z, Ichikawa J, Dai J, Meltzer HY (2004) Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 493:75-83
52. Markstein R, Hoyer D, Engel G (1986) 5-HT1A-receptors mediate stimulation of adenylate cyclase in rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 333:335-341
53. Martín-Ruiz R, Puig MV, Celada P, Shapiro D, Roth BL, Mengod G, Artigas F (2001a) Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci 21:9856-9866
54. Martín-Ruiz R, Ugedo L, Honrubia MA, Mengod G, Artigas F (2001b) Control of serotonergic neurons in rat brain by dopaminergic receptors outside the dorsal raphe nucleus. J Neurochem 77:762-775
55. Meltzer HY (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21:S106-S115
56. 1A) receptors. J Pharmacol Exp Ther 295:853-861
57. 1A receptors coupled to mitogen-activated protein kinase. Eur J Pharmacol 424:13-17
58. Momiyama T, Amano T, Todo N, Sasa M (1996) Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area. Eur J Pharmacol 310:1-8
59. Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects - a comprehensive literature review. CNS Drugs 19:1-93
60. 1A receptors. Eur Neuropsychopharmacol 16(Suppl 4):S232
61. Parks CL, Robinson PS, Sibille E, Shenk T, Toth M (1998) Increased anxiety of mice lacking the serotonin(1A) receptor. Proc Natl Acad Sci U S A 95:10734-10739
62. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic, Sydney
63. Puig MV, Artigas F, Celada P (2005) Modulation of the activity of pyramidal neurons in rat prefrontal cortex by raphe stimulation in vivo: involvement of serotonin and GABA. Cereb Cortex 15:1-14
64. 1A receptor activation. Eur J Pharmacol 338:R3-R5
65. Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH (2000) 5-HT (1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 48:229-237
66. Rouquier L, Claustre Y, Benavides J (1994) Alpha-1 adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study. Eur J Pharmacol 261:59-64
67. Santana N, Bortolozzi A, Serrats J, Mengod G, Artigas F (2004) Expression of Serotonin(1A) and Serotonin(2A) receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 14:1100-1109
68. 1A receptors: studies in transfected HeLa cells. Neuropharmacology 36:429-438
69. Semba J, Watanabe A, Kito S, Toru M (1995) Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology 34:785-791
70. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411
71. 1B agonists: a comparative study with dorsal raphe neurons. Neuropharmacology 27:707-715
72. 1A receptor activation. Neuropsychopharmacology 21:622-631
73. Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Kurachi M, Uehara T, Sumiyoshi S, Sumiyoshi C, Meltzer HY (2001) The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry 49:861-868
74. Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Uehara T, Kurachi M, Meltzer HY (2000) Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacol 20:386-388
75. Tadori Y, Miwa T, Tottori K, Burris KD, Stark A, Mori T, Kikuchi T (2005) Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Pharmacol 515:10-19
76. Tamminga CA (2002) Partial dopamine agonists in the treatment of psychosis. J Neural Transm 109:411-420
77. Vandermaelen CP, Aghajanian GK (1983) Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices. Brain Res 289:109-119
78. Weinberger DR, Aloia MS, Goldberg TE, Berman KF (1994) The frontal lobes and schizophrenia. J Neuropsychiatry Clin Neurosci 6:419-427
79. Williams GV, Goldman-Rakic PS (1995) Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376:572-575
80. 11C]raclopride. Neuropsychopharmacology 27:248-259
81. Zocchi A, Fabbri D, Heidbreder CA (2005) Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci Lett 387:157-161